BXRX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 vas. 2024 @ 22:53):

Stats
Dzisiejszy wolumen	310 872
Średni wolumen	424 847
Kapitalizacja rynkowa	950 330
EPS	$0 ( 2024-03-07 )
Następna data zysków	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.000232
ATR14	$0.00100 (4.59%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-09	Mcandrew Natalie	Buy	0
2023-07-03	Kim Yong Chan	Sell	0	Common Stock
2023-07-03	Kim Yong Chan	Sell	4 520 066	Series X Preferred Stock
2022-12-15	Henwood Geraldine	Buy	1 200	Common Stock
2022-06-15	Ashton William	Buy	39 473	Common Stock

INSIDER POWER
-98.49
Last 86 transactions
Buy: 13 000 393 \| Sell: 13 896 192

Baudax Bio Inc Korelacja

10 Najbardziej pozytywne korelacje
RMRM	0.959
TANH	0.956
GNUS	0.956
MOTS	0.95
BLUE	0.934
HYW	0.934
VERB	0.928
RLAY	0.925
BNTX	0.922
AGIL	0.913

10 Najbardziej negatywne korelacje
LMRK	-0.96
AGFS	-0.951
QADA	-0.93
RMBS	-0.929
LOPE	-0.927
EYEG	-0.923
STTK	-0.919
SNSR	-0.91
KE	-0.91
GRID	-0.908

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Baudax Bio Inc Finanse

Annual	2022
Przychody:	$1.27M
Zysk brutto:	$-5.74M (-452.32 %)
EPS:	$-177.30

FY	2022
Przychody:	$1.27M
Zysk brutto:	$-5.74M (-452.32 %)
EPS:	$-177.30

FY	2021
Przychody:	$1.08M
Zysk brutto:	$-1.37M (-126.39 %)
EPS:	$-2 287 839

FY	2020
Przychody:	$493 000
Zysk brutto:	$-1.24M (-251.32 %)
EPS:	$-8 806 947

Financial Reports:

No articles found.

Baudax Bio Inc

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Aktualne aktualizacje dla Baudax Bio Inc [BXRX]

Upcoming Earnings Alert